Autologous Multi-Lineage Potential Cells

Name: Autologous Multi-Lineage Potential Cells in Acute Myeloid Leukaemia Recurrent
Creator: Floatz
License: https://terminal.floatz.ai/terms

Acute Myeloid Leukaemia Recurrent

Lai Corporation Pty. Ltd.Cell therapyPhase 1Dormant

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

685 Active assets in the Acute Myeloid Leukaemia Recurrent cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China	Phase 3	BBB
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →